Navigation Links
USC researchers identify novel approach for suppressing prostate cancer development
Date:11/24/2008

Los Angeles, Calif. Nov. 24, 2008Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

Researchers say the upcoming study in the Proceedings of the National Academy of Sciencesnow available onlinemay lead to a novel cancer therapy for humans.

"This research has far-reaching implications in a wide range for human cancers," says Amy Lee, Ph.D., the study's principal investigator and the associate director for basic research and holder of the Freeman Cosmetics Chair at the USC/Norris Comprehensive Cancer Center, and professor of biochemistry and molecular biology at the Keck School of Medicine of USC. "It is a breakthrough study."

Prostate cancer is the most common cancer in men and develops through successive stages. The glucose-regulated protein GRP78 has been identified as a crucial entity in the development of prostate cancer by promoting cancer cell proliferation, mediating oncogenic signaling and protecting cancer cells against cell death resulting from the stress of tumor development, Lee explains. By suppressing GRP78 expression or activity, the USC researchers found that they could block prostate cancer activation and development resulting from the loss of PTEN, a powerful tumor suppressor gene for a number of human cancers.

Researchers spent more than three years monitoring prostate cancer development in animal models that had been genetically engineered to have both the GRP78 and PTEN tumor suppressor genes inactivated. The research was conducted by Yong Fu, a Ph.D. candidate at the Keck School of Medicine of USC and the first author on the study, in collaboration with Ph.D candidates Shiuan Wey, Miao Wang, Risheng Ye and Chun-Peng Liao and Pradip Roy-Burman, M.D., professor of pathology, biochemistry and molecular biology at the Keck School.

Future research should test the role of GRP78 in other types of cancer and isolate drugs that inhibit GRP78, Lee says. "To our knowledge, this is the first demonstration that inactivation of a specific molecular chaperone from the mouse prostate epithelial cells can potently block prostate cancer development and suppress the activation of AKT, which is a protein kinase that promotes cell proliferation and survival and is a major factor in many types of cancer," Lee says. "With the recent advances in identifying agents that suppress GRP78 expression, anti-GRP78 therapy may open up an entirely new approach to stop human cancer."


'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Related medicine news :

1. Researchers identify new leprosy bacterium
2. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
3. Researchers discover strategy for predicting the immunity of vaccines
4. Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find
5. Researchers ID Suite of Genes in Aging Process
6. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Leeds researchers reshape the future of drug discovery
9. UNC researchers find clue to stopping breast-cancer metastasis
10. U of U researchers to use patients own stem cells to treat heart failure
11. Researchers identify toehold for HIVs assault on brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: